WTO TRIPS Council (October 2020): European Union dismisses concerns that IPRs are a barrier to COVID-19 medicines and technologies

On Friday, 16 October 2020, the European Union provided the following perspectives during a three hour debate on the proposed waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 co-sponsored by Eswatini, Kenya,… Continue Reading

WTO TRIPS Council (October 2020): Hungary answers queries posed by South Africa regarding Hungarian compulsory licensing provisions

At the October 2020 session of the World Trade Organization’s (WTO) TRIPS Council, under agenda item 1, IP measures in the context of COVID-19, the European Union read out Hungary’s detailed responses to questions posed in July 2020 (at the… Continue Reading

WTO TRIPS Council (October 2020): South Africa issues clarion call urging support for TRIPS waiver proposal

On Friday, 16 October 2020, members of the World Trade Organization’s (WTO) TRIPS Council held a three hour debate on the proposal (IP/C/W/669) first tabled by India and South Africa for a waiver from certain provisions of the TRIPS Agreement… Continue Reading

Contracts Obtained by KEI via FOIA

Biomedical Advanced Research and Development Authority (BARDA) Agreements signed or expanded in 2020 to cover research on COVID-19 vaccines or therapeutics: AstraZeneca – vaccine. HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020. HHS/ASPR/BARDA-AstraZeneca Modification of OTA… Continue Reading

Taxpayers are subsidizing 80 percent of Regeneron’s COVID-19 treatment’s R&D costs

Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent… Continue Reading

KEI on Moderna’s Oct 8, 2020 Statement on Intellectual Property Matters during the COVID-19 Pandemic

(More on KEI’s work on coronavirus here: https://www.keionline.org/coronavirus, and on Moderna, here: https://www.keionline.org/moderna) Oct 8, 2020 Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine… Continue Reading

KEI written statement at the WHO Executive Board special session: Update on implementation of resolution WHA73.1 (2020) on the COVID-19 response

Knowledge Ecology International (KEI) is an accredited non-state actor at the World Health Organization (WHO). This is our statement at the WHO Executive Board Special Session on the COVID-19 response. https://extranet.who.int/nonstateactorsstatements/print/book/export/html/3916?destination=node/3916 Knowledge Ecology International Meeting: EB Special session on the… Continue Reading